Q1 2026 · 13F-HR
FCPM III SERVICES B.V.holdings as filed
Filed 2026-05-15 · accession 0001193125-26-225423
$722.2M
Reported value
10
Positions
2026-03-31
Period end
The Brief · FCPM III SERVICES B.V. · Q1 2026
AI · grounded in 13F
FCPM III SERVICES B.V. established a new position in DMRA valued at $63.2M. The fund closed its entire position in RAPT, reducing exposure by $62.1M. Additionally, the fund increased its holdings in VOR by 13.8% and trimmed its stake in DYN by 15%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $294.5M | 40.8% | 9,198,900 | Common | SHARED |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $84.2M | 11.7% | 4,644,386 | Common | SHARED |
| 929033207 | VOR | VOR BIOPHARMA INC | $73.5M | 10.2% | 4,117,354 | Common | SHARED |
| 29286M105 | — | ENGENE HOLDINGS INC | $65.6M | 9.08% | 9,632,561 | Common | SHARED |
| 56565P103 | MPLT | MAPLIGHT THERAPEUTICS INC | $65.6M | 9.08% | 3,226,400 | Common | SHARED |
| 36322Q206 | DMRA | DAMORA THERAPEUTICS INC | $63.2M | 8.75% | 2,441,000 | Common | SHARED |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $30.8M | 4.27% | 1,677,852 | Common | SHARED |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $21.5M | 2.97% | 2,808,368 | Common | SHARED |
| 088786108 | BCYC | BICYCLE THERAPEUTICS PLC | $16.1M | 2.23% | 3,468,430 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $7.3M | 1.01% | 2,878,148 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.